Sugi Predict

Sugi Predict / Compounds / SCHEMBL3752495

SCHEMBL3752495

SCHEMBL3752495

CCOC(=O)c1cn(CC)nc1I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.44
▸ NPC1 O15118 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KMT2A Q03164 4/20 0.40
▸ JMJD6 Q6NYC1 1/20 0.40
▸ BAZ2B Q9UIF8 1/20 0.40
▸ BAZ2A Q9UIF9 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ TEAD2 Q15562 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27085786 0.88 TEAD2 (0.43) TSHRKMT2AJMJD6BAZ2BBAZ2A
SCHEMBL27086400 0.85 TSHR (0.40) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL645580 0.83 TSHR (0.47) TSHRNPC1RAB9AKMT2AJMJD6
SCHEMBL23273647 0.83 L3MBTL1 (0.47) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL22897231 0.83 LMNA (0.45) TSHRLMNACSNK1D
SCHEMBL4851162 0.82 TSHR (0.46) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL23273667 0.82 NPC1 (0.49) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1458217 0.82 NPC1 (0.49) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL31352245 0.81 BAZ2B (0.47) TSHRNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL175330 0.81 ALDH1A1 (0.46) TSHRNPC1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF SCHRÖDINGER, INC. 2025-08-21 — — US disclosed
US-12325697-B2 CBL-B modulators and uses thereof NIMBUS CLIO, INC. (US) 2025-06-10 — — US disclosed
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2025-02-27 — — US disclosed
EP-4460505-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2024-11-13 — — EP disclosed
CN-117858707-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 — — CN disclosed
EP-4319756-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-02-14 — — EP disclosed
WO-2023185986-A1 BCL-XL INHIBITORS BEIGENE , LTD. (KY) 2023-10-05 — — WO disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 — — WO disclosed
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-23 — — US disclosed
WO-2022217276-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-10-13 — — WO disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 — — EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 — — US disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 TSHR 4380/4885NPC1 2197/4885MAPT 562/4885
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES IL1B, NLRP3, IL1A TSHR 4687/4885NPC1 1533/4885MAPT 1825/4885
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC TSHR 3636/4885NPC1 1290/4885MAPT 3660/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 TSHR 4691/4885NPC1 1945/4885MAPT 330/4885
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 TSHR 625/4885NPC1 3296/4885MAPT 2822/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 TSHR 4380/4885NPC1 2197/4885MAPT 562/4885
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC TSHR 3636/4885NPC1 1290/4885MAPT 3660/4885
US-12325697-B2 CBL-B modulators and uses thereof CBLB, CBL, CBLC TSHR 3636/4885NPC1 1290/4885MAPT 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.